International Scholarly Research Notices / 2013 / Article / Tab 1

Research Article

Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

Table 1

Demographics and baseline characteristics of patients enrolled into the immunology substudy of GRACE.

ParameterAll HIV+ patients
( )
Virologically suppresseda patients at Wk 48 ( )

Sex, (%)Men19 (59.4)13 (68.4)
Women13 (40.6)6 (31.6)
Race, (%)Black15 (46.9)8 (42.1)
Hispanic10 (31.3)6 (31.6)
White7 (21.9)5 (26.3)
Mean (SD) viral load, log10 copies/mL4.74 (0.84)4.76 (0.82)
Median (range) CD4+ count, cells/mm3191 (2, 463)222 (2, 398)

HIV-1 RNA < 50 copies/mL at Wk 48 (or at Wks 36 and 52 if a Wk 48 sample was not available).

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.